Information on dosage, strength, pricing, and administration costs needed to estimate costs of treatments sequences.
params_costs_tx
A list with the following elements:
A data.table containing information on dosage for each
agent used for treatments that can be included in a treatment sequence. The variables
strength1, strength2, quantity1, quantity2, units_per_day,
and duration_days can be modified to change annualized costs.
Name of the agent used in the treatment; combination therapies will have more than one agents.
Amount, number. and frequency of doses over a specified time period.
Specified amount of medication taken at one time. By default, doses based on body surface area (BSA) and weight are based on mean BSA and weight, respectively.
The unit used to compute costs.
The amount of the drug in a single dosage form (e.g., tablet or vial).
If a unit consists of multiple dosage forms, then the amount of the drug
in the dosage form not included in strength1.
Quantity of dosage form specified in strength1 in a unit.
Quantity of dosage form specified in strength2 in a unit.
Number of units of the treatment (based on dosage) used per day.
Number of days to use the treatment. If used until progression, then
must equal Inf.
Source for dosage information.
A data.table of acquisition costs by agent and strength.
Default costs are based on wholesale acquisition costs (WACs). The variable
acquisition_cost can be modified to change annualized acquisition costs.
Name of the agent
The amount of the agent in a given unit of the dosage form.
The acquisition cost of an agent for a given strength.
Source used for acquisition cost.
Name of the agent.
Lower bound for discount and rebates as a
proportion of acquisition_cost in the acquisition_costs table.
Assumed to follow a uniform distribution in the probabilistic sensitivity analysis.
Upper bound for discount and rebates as a
proportion of acquisition_cost in the acquisition_costs table.
Assumed to follow a uniform distribution in the probabilistic sensitivity analysis.
A data.table of administration costs. The variable costs
can be modified to change annualized administration costs.
Name of the agent.
The costs of administering an agent.
Source used for administration cost.
A lookup data.table used to match treatments from the treatments
table to agents comprising a particular treatment.
Name of treatment.
Name of first agent used for treatment.
Name of second agent used for treatment.
Name of third agent used for treatment.
Name of fourth agent used for treatment.
print(params_costs_tx)#> $dosage #> agent_name dosage dose #> 1: erlotinib 150 mg orally, once daily 150.00 #> 2: gefitinib 250 mg orally, daily 250.00 #> 3: afatinib 40 mg orally, once daily 40.00 #> 4: dacomitinib 45 mg orally, once daily 45.00 #> 5: osimertinib 80 mg orally, once daily 80.00 #> 6: cisplatin 75mg/m2, 1x/cycle, 6 21-day cycles 142.50 #> 7: pemetrexed 500 mg, 1x/cycle, 6 21-day cycles 500.00 #> 8: bevacizumab 15mg/kg IV every 3 weeks with carboplatin/paclitaxel 1111.95 #> 9: nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks 240.00 #> 10: pembrolizumab 200 mg every 3 weeks 200.00 #> 11: atezolizumab 1200 mg as an IV infusion over 60 min every 3 weeks 1200.00 #> unit strength1 strength2 #> 1: 150mg tablet 150mg tablet <NA> #> 2: 250mg tablet 250mg tablet <NA> #> 3: 40mg tablet 40mg tablet <NA> #> 4: 45mg tablet 45mg tablet <NA> #> 5: 80mg tablet 80mg tablet <NA> #> 6: 1 100mg/100ml vial, 1 50mg/50ml vial 100mg/100ml vial 50mg/50ml vial #> 7: 500mg vial 500mg vial <NA> #> 8: 3 400mg/16ml vials 400mg/16ml vial <NA> #> 9: 2 100mg/10ml, 1 40mg/4ml 100mg/10ml vial 40mg/4ml vial #> 10: 2 100mg/4ml vial 100mg/4ml vial <NA> #> 11: 1200mg/20ml vial 1200mg/20ml vial <NA> #> quantity1 quantity2 units_per_day duration_days #> 1: 1 0 1.00000000 Inf #> 2: 1 0 1.00000000 Inf #> 3: 1 0 1.00000000 Inf #> 4: 1 0 1.00000000 Inf #> 5: 1 0 1.00000000 Inf #> 6: 1 1 0.04761905 126 #> 7: 1 0 0.04761905 126 #> 8: 3 0 0.04761905 Inf #> 9: 2 1 0.07142857 730 #> 10: 2 0 0.04761905 730 #> 11: 1 0 0.04761905 730 #> source #> 1: FDA label #> 2: FDA label #> 3: FDA label #> 4: FDA label #> 5: FDA label #> 6: ICER Report Treatment Options for Advanced Non-Small Cell Lung Cancer: Effectiveness, Value and Value Based Price Benchmarks (2016) #> 7: <NA> #> 8: FDA label #> 9: FDA label #> 10: FDA label #> 11: FDA label #> #> $acquisition_costs #> agent_name strength acquisition_cost #> 1: erlotinib 150mg tablet 281.7133 #> 2: gefitinib 250mg tablet 257.0590 #> 3: afatinib 40mg tablet 235.0500 #> 4: dacomitinib 45mg tablet 407.3900 #> 5: osimertinib 80mg tablet 487.2157 #> 6: cisplatin 50mg/50ml vial 14.5100 #> 7: cisplatin 100mg/100ml vial 35.0000 #> 8: cisplatin 200mg/200ml vial 100.0000 #> 9: pemetrexed 100mg vial 676.5200 #> 10: pemetrexed 500mg vial 3382.6000 #> 11: carboplatin 50mg/5ml 5.9900 #> 12: carboplatin 150mg/15ml 14.2000 #> 13: carboplatin 450mg/45ml 32.9900 #> 14: carboplatin 600mg/60ml 43.9900 #> 15: gemcitabine 200mg/2mL 3.7000 #> 16: gemcitabine 1g/10mL 3.6900 #> 17: gemcitabine 2g/20mL 4.1000 #> 18: docetaxel 160mg/16ml 34.3800 #> 19: docetaxel 80mg/8ml 34.3800 #> 20: docetaxel 20mg/2ml 34.3800 #> 21: paclitaxel 300mg/50ml 55.0000 #> 22: paclitaxel 100mg/16.7ml 24.5000 #> 23: paclitaxel 30mg/5ml 10.5000 #> 24: bevacizumab 100mg/4ml vial 199.2350 #> 25: bevacizumab 400mg/16ml vial 199.2350 #> 26: nivolumab 100mg/10ml vial 262.2080 #> 27: nivolumab 40mg/4ml vial 262.2075 #> 28: pembrolizumab 100mg/4ml vial 1162.4100 #> 29: atezolizumab 1200mg/20ml vial 444.0270 #> agent_name strength acquisition_cost #> source #> 1: ProspectoRx; WAC price 12/15/2017 #> 2: ProspectoRx; WAC price 1/1/2018 #> 3: ProspectoRx; WAC price 9/1/2017 #> 4: Public announcement #> 5: ProspectoRx; WAC price 1/1/2018 #> 6: ProspectoRx; WAC price 3/8/2018 #> 7: ProspectoRx; WAC price 9/12/2016 #> 8: ProspectoRx; WAC price 10/17/2016 #> 9: ProspectoRx; WAC price 3/30/2018 #> 10: ProspectoRx; WAC price 3/30/2018 #> 11: AnalySource 201875 (NDC: 47781-0603-20) #> 12: AnalySource 201875 (NDC: 50742-0446-15) #> 13: AnalySource 201875 (NDC: 47781-0605-94) #> 14: AnalySource 201875 (NDC: 47781-0606-94) #> 15: ProspectoRx; WAC price 5/1/2018 #> 16: ProspectoRx; WAC price 5/1/2018 #> 17: ProspectoRx; WAC price 5/1/2018 #> 18: ProspectoRx; WAC price 9/5/2018 #> 19: ProspectoRx; WAC price 9/28/2018 #> 20: ProspectoRx; WAC price 9/28/2018 #> 21: ProspectoRx; WAC price 1/23/2018 #> 22: ProspectoRx; WAC price 1/23/2018 #> 23: ProspectoRx; WAC price 1/23/2018 #> 24: ProspectoRx; WAC price 7/1/2018 #> 25: ProspectoRx; WAC price 7/1/2018 #> 26: ProspectoRx; WAC price 4/1/2018 #> 27: ProspectoRx; WAC price 4/1/2018 #> 28: ProspectoRx; WAC price 3/22/2018 #> 29: ProspectoRx; WAC price 7/1/2018 #> source #> #> $discounts #> agent_name discount_lower discount_upper #> 1: erlotinib 0.2 0.3 #> 2: gefitinib 0.2 0.3 #> 3: afatinib 0.2 0.3 #> 4: dacomitinib 0.2 0.3 #> 5: osimertinib 0.2 0.3 #> 6: cisplatin 0.2 0.3 #> 7: pemetrexed 0.2 0.3 #> 8: bevacizumab 0.2 0.3 #> 9: nivolumab 0.2 0.3 #> 10: pembrolizumab 0.2 0.3 #> 11: atezolizumab 0.2 0.3 #> #> $administration_costs #> agent_name administration_cost source #> 1: erlotinib 0.00 N/A #> 2: gefitinib 0.00 N/A #> 3: afatinib 0.00 N/A #> 4: dacomitinib 0.00 N/A #> 5: osimertinib 0.00 N/A #> 6: cisplatin 91.72 CPT 96417, 96415 #> 7: pemetrexed 136.15 CPT 96413 #> 8: bevacizumab 91.72 CPT 96413, 96415, 96417 #> 9: nivolumab 136.15 CPT 96413 #> 10: pembrolizumab 136.15 CPT 96413 #> 11: atezolizumab 136.15 CPT 96413 #> #> $lookup #> tx_name agent_name1 agent_name2 agent_name3 #> 1: erlotinib erlotinib <NA> <NA> #> 2: gefitinib gefitinib <NA> <NA> #> 3: afatinib afatinib <NA> <NA> #> 4: dacomitinib dacomitinib <NA> <NA> #> 5: osimertinib osimertinib <NA> <NA> #> 6: PBDC cisplatin pemetrexed <NA> #> 7: bevacizumab bevacizumab <NA> <NA> #> 8: nivolumab nivolumab <NA> <NA> #> 9: pembrolizumab pembrolizumab <NA> <NA> #> 10: atezolizumab atezolizumab <NA> <NA> #> 11: PBDC + bevacizumab cisplatin pemetrexed bevacizumab #> 12: PBDC + nivolumab cisplatin pemetrexed nivolumab #> 13: PBDC + pembrolizumab cisplatin pemetrexed pembrolizumab #> 14: PBDC + atezolizumab cisplatin pemetrexed atezolizumab #> 15: PBDC + bevacizumab + nivolumab cisplatin pemetrexed bevacizumab #> 16: PBDC + bevacizumab + pembrolizumab cisplatin pemetrexed bevacizumab #> 17: PBDC + bevacizumab + atezolizumab cisplatin pemetrexed bevacizumab #> agent_name4 #> 1: <NA> #> 2: <NA> #> 3: <NA> #> 4: <NA> #> 5: <NA> #> 6: <NA> #> 7: <NA> #> 8: <NA> #> 9: <NA> #> 10: <NA> #> 11: <NA> #> 12: <NA> #> 13: <NA> #> 14: <NA> #> 15: nivolumab #> 16: pembrolizumab #> 17: atezolizumab #>